PAUL KUDER: Open Payments
NPI 1801567367 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,955 in 198 payments from 14 companies in 2025. Trend: 2023 $1,763 · 2024 $2,002 · 2025 $2,955
Food & beverage: $2,871Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $362 |
| Madrigal Pharmaceuticals | 14 | $258 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $247 |
| Janssen Biotech, Inc. | 10 | $192 |
| Ardelyx, Inc. | 11 | $191 |
| Ipsen Biopharmaceuticals, Inc | 18 | $189 |
| QOL Medical, LLC | 6 | $170 |
| Phathom Pharmaceuticals, Inc. | 19 | $152 |
| Gilead Sciences, Inc. | 12 | $148 |
Products named: ENTYVIO, REZDIFFRA, XIFAXAN, RINVOQ, TREMFYA, IBSRELA, IQIRVO, Sucraid.
Industry payments across TX — which companies pay providers there.
